Piramal Enterprises to acquire Ash Stevens Inc for more than Rs 350 crore
"Ash Stevens will add high potency capabilities to the services we offer our customers," Vivek Sharma, Pharma Solutions business CEO, Piramal Enterprises, said.
The deal bolsters the company’s manufacturing capabilities and adds several biotech and pharmaceutical clients. Ash Stevens has developed high potency active pharmaceutical ingredients or APIs with an impeccable safety record of working with high potency anti-cancer agents and other such therapeutics, Piramal Enterprises said in a statement.
Michigan-based Ash Stevens will be the third facility for Piramal Enterprises in the North American market. It has Coldstream Labs facility located in Kentucky and Torcan in Toronto that is used to make complex high value APIs.
According to Vivek Sharma, CEO of Piramal Pharma Solutions, the facilities with a differentiated platform and geographical proximity to clients are critical for building strategic partnerships. Sharma said the latest buyout can be synergistic with the antibody drug conjugates and injectable business.
On Bombay Stock Exchange, shares of Piramal Enterprises closed at Rs 1,780.10, up 6.20 per cent from the previous close..
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.